Inozyme Pharma (INZY) Projected to Post Earnings on Tuesday

Posted by Defense World Staff on Mar 9th, 2025

Inozyme Pharma (NASDAQ:INZY – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect Inozyme Pharma to post earnings of ($0.42) per share for the quarter.

Inozyme Pharma Trading Down 6.5 %

NASDAQ INZY opened at $1.15 on Friday. Inozyme Pharma has a one year low of $1.04 and a one year high of $7.80. The company has a 50-day simple moving average of $1.62 and a 200-day simple moving average of $3.37. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The firm has a market capitalization of $73.88 million, a PE ratio of -0.74 and a beta of 1.32.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Wells Fargo & Company decreased their price target on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, January 13th. Piper Sandler decreased their price target on shares of Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, January 13th. Wedbush reaffirmed an “outperform” rating and issued a $12.00 price target on shares of Inozyme Pharma in a report on Friday, January 10th. HC Wainwright lifted their price objective on shares of Inozyme Pharma from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Finally, Raymond James assumed coverage on shares of Inozyme Pharma in a research report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price objective on the stock. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Inozyme Pharma currently has an average rating of “Buy” and a consensus target price of $18.33.

Read Our Latest Research Report on INZY

Inozyme Pharma Company Profile

(Get Free Report)

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.